Dendritic Cell Vaccine for Breast Cancer
(DecipHER Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot be on other investigational drugs or active cancer treatments. It's best to discuss your current medications with the trial team to see if they are allowed.
Will I have to stop taking my current medications?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot be on other investigational agents or active cancer treatments, and you should not be using long-term corticosteroids or have received a live vaccine within 30 days before joining the trial.
What data supports the effectiveness of the dendritic cell vaccine treatment for breast cancer?
Research shows that dendritic cell vaccines targeting HER2 can generate immune responses that delay tumor growth and improve survival in preclinical models of HER2-positive breast cancer. Additionally, small studies in patients with high-risk breast cancer or metastatic cancers expressing HER2 have shown that these vaccines are safe and can induce modest immune responses, suggesting potential benefits in preventing recurrence and enhancing antitumor immunity.12345
What data supports the effectiveness of the dendritic cell vaccine treatment for breast cancer?
Research shows that dendritic cell vaccines targeting HER2 can generate immune responses that delay tumor growth and improve survival in preclinical models of HER2-positive breast cancer. Additionally, small studies in patients with high-risk breast cancer have shown that these vaccines are safe and can induce modest immune responses, suggesting potential benefits in preventing recurrence.12345
Is the dendritic cell vaccine for breast cancer safe for humans?
Is the Dendritic Cell Vaccine for Breast Cancer safe for humans?
How is the dendritic cell vaccine treatment for breast cancer different from other treatments?
The dendritic cell vaccine for breast cancer is unique because it uses the body's own immune cells, called dendritic cells, to target and attack cancer cells by priming them with specific proteins (HER2 and HER3) found on cancer cells. This approach aims to stimulate a targeted immune response, potentially offering a new way to treat cancers that overexpress these proteins, unlike traditional therapies that may not specifically target these antigens.12789
How is the dendritic cell vaccine treatment for breast cancer different from other treatments?
The dendritic cell vaccine for breast cancer is unique because it uses the body's own immune cells, called dendritic cells, to target and attack cancer cells that overexpress the HER2 or HER3 proteins. This approach aims to stimulate a specific immune response against the cancer, potentially offering a more targeted and personalized treatment compared to traditional therapies.12578
What is the purpose of this trial?
The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast cancer.
Research Team
Ricardo Costa, MD
Principal Investigator
Moffitt Cancer Center
Eligibility Criteria
This trial is for adults over 18 with early-stage Triple Negative or HR low positive breast cancer, who can undergo standard chemotherapy and surgery. Participants need normal organ/marrow function, no severe autoimmune diseases, not pregnant/nursing, and no recent vaccines or other cancer treatments.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Dose Escalation
Dose escalation to determine the maximum tolerated dose (MTD) of HER2- and HER3-primed DC1 study vaccines
Treatment
Participants receive DC1 injections and standard of care chemotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- HER2-primed Dendritic cells
- HER3-primed Dendritic cells
Find a Clinic Near You
Who Is Running the Clinical Trial?
H. Lee Moffitt Cancer Center and Research Institute
Lead Sponsor
The Shulas' Foundation
Collaborator